TOCILIZUMAB

tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: Balance of supply - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 4 # of repeats: 3 DPMQ: $760.99 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra ACTPen
Avtozma
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: First continuing treatment

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: First continuing treatment - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 4 # of repeats: 5 DPMQ: $760.99 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra ACTPen
Avtozma
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Active giant cell arteritis
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 4 # of repeats: 6 DPMQ: $760.99 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra ACTPen
Avtozma
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Balance of supply - Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 4 # of repeats: 3 DPMQ: $760.99 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra ACTPen
Avtozma
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 4 # of repeats: 1 DPMQ: $760.99 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra ACTPen
Avtozma
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices
Manner of administration:Injection
General Schedule
Authority Required (STREAMLINED)

Restriction (Streamlined authority code: 17742)

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 4 # of repeats: 2 DPMQ: $760.99 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra ACTPen
Avtozma
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Active giant cell arteritis
Treatment phase: Initial treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 4 # of repeats: 5 DPMQ: $760.99 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra ACTPen
Avtozma
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: First continuing treatment

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Subsequent continuing treatment

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Balance of supply - Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 4 # of repeats: 5 DPMQ: $760.99 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra ACTPen
Avtozma
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient weighing at least 30 kg)

Restriction

Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing at least 30 kg)

Restriction

Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months in a patient weighing at least 30 kg)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 4 # of repeats: 3 DPMQ: $760.99 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra ACTPen
Avtozma
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices
Manner of administration:Injection
General Schedule
Authority Required (STREAMLINED)

Restriction (Streamlined authority code: 14088)

Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Continuing treatment in a patient weighing at least 30 kg
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 4 # of repeats: 5 DPMQ: $760.99 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra ACTPen
Avtozma